Other languages BeiGene, Ltd. Deutsche Boerse AG

Equities

49B

KYG1146Y1017

Real-time Estimate Tradegate Other stock markets 09:32:21 2024-05-22 am EDT			5-day change	1st Jan Change
12.1 ^EUR	+4.31%		+3.48%	-4.03%

May. 21	Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India	MT
May. 14	BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India	May. 21
EHA2024: BeiGene präsentiert neues Hämatologie-Portfolio und Pipeline-Daten	May. 15
BeiGene présente de nouvelles données de portefeuille et de pipeline d'hématologie à l'EHA2024	May. 15
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024	May. 14
BeiGene meldet Finanzergebnisse für das erste Quartal 2024 und aktuelle Geschäftsentwicklungen	May. 09
Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up	May. 08
BeiGene presenta los resultados financieros del primer trimestre de 2024 y actualiza sus actividades	May. 08
BeiGene présente ses résultats financiers du premier trimestre 2024 et ses dernières nouvelles commerciales	May. 08
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	May. 08
BeiGene's Q1 Loss Narrows as Revenue Rises	May. 08
BeiGene, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
BeiGene, Ltd. Anticipates Opening of Biologics Manufacturing Facility and Clinical R&D Center at the Princeton West Innovation Campus in Hopewell, New Jersey, in July 2024	May. 08
Globaler Onkologie-Innovator BeiGene präsentiert auf der ASCO-Jahrestagung 2024 neue Daten aus dem gesamten Portfolio für Hämatologie und solide Tumore	Apr. 25
BeiGene, innovateur mondial en oncologie, présente de nouvelles données sur l’ensemble de son portefeuille en hématologie et en tumeurs solides lors de la réunion annuelle de l’ASCO 2024	Apr. 25
BeiGene erhält von der EU-Kommission die Zulassung für Tislelizumab zur Behandlung von nicht kleinzelligem Lungenkrebs	Apr. 23
BeiGene reçoit l’approbation de la Commission européenne pour le tislelizumab dans le traitement du cancer du poumon non à petites cellules	Apr. 23
Sector Update: Health Care Stocks Rise in Afternoon Trading	Apr. 23
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	Apr. 23
Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	Apr. 23
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	Apr. 23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BeiGene, Ltd. Deutsche Boerse AG

Equities

49B

KYG1146Y1017

Other languages

Filters